Efficacy and Safety of Sitafloxacin in the Treatment of Acute Bacterial Infection: A Meta-analysis of Randomized Controlled Trials

Antibiotics
Chao-Kun ChenChih-Cheng Lai

Abstract

This meta-analysis aimed to assess the efficacy and safety of sitafloxacin in treating acute bacterial infection. PubMed, Embase, and Cochrane databases were searched up to August 13, 2019. Only randomized controlled trials (RCTs) evaluating sitafloxacin and comparators in the treatment of acute bacterial infections were included. The outcomes were clinical and microbiological responses and the risk of adverse event (AE). Five RCTs were enrolled, including 375 and 381 patients who received sitafloxacin and the comparator, respectively. Overall, the clinical response rate of sitafloxacin in the treatment of acute bacterial infections was 94.6%, which was noninferior to that of the comparator (92.5%) (odds ratio (OR), 1.01; 95% CI, 0.24-4.32; I2 = 66%). For patients with complicated urinary tract infection (cUTI)/acute pyelonephritis (APN), the clinical response rate of sitafloxacin and the comparator was 96.9% and 91.3%, respectively (OR, 2.08; 95% CI, 0.35-12.44; I2 = 54%). For patients with pneumonia, the clinical response rate of sitafloxacin was 88.6%, which was comparable to that of the comparator (OR, 0.36; 95% CI, 0.11-1.21; I2 = 0%). The microbiological response of sitafloxacin was 82.0%, which was noninferior to that of...Continue Reading

References

Apr 21, 2011·Drugs·Gillian M Keating
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Nov 28, 2012·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Jiro FujitaShigeru Kohno
Jan 28, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Tatsuya NakamuraYasunao Wada
Mar 26, 2014·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yu-Shan HuangShan-Chwen Chang
Jun 8, 2017·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Chitprasong MalaisriSasisopin Kiertiburanakul
Apr 8, 2019·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Kazuhiro TatedaUNKNOWN Levofloxacin surveillance group
May 23, 2019·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Taiga MiyazakiHiroshi Mukae

❮ Previous
Next ❯

Software Mentioned

Review Manager
Cochrane Risk of Bias Assessment Tool

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.